Corcept Therapeutics (Corcept Therapeutics) EBIT per Share : $0.97 (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Corcept Therapeutics EBIT per Share?

Corcept Therapeutics's EBIT per Share for the three months ended in Dec. 2023 was $0.29. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.97.

During the past 12 months, the average EBIT per Share Growth Rate of Corcept Therapeutics was -1.10% per year. During the past 3 years, the average EBIT per Share Growth Rate was -2.40% per year. During the past 5 years, the average EBIT per Share Growth Rate was 4.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Corcept Therapeutics's EBIT per Share or its related term are showing as below:

CORT' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -3.9 Med: 11.9 Max: 117.9
Current: -2.4

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Corcept Therapeutics was 117.90% per year. The lowest was -3.90% per year. And the median was 11.90% per year.

CORT's 3-Year EBIT Growth Rate is ranked worse than
56.78% of 1305 companies
in the Biotechnology industry
Industry Median: 3.2 vs CORT: -2.40

Corcept Therapeutics's EBIT for the three months ended in Dec. 2023 was $31.7 Mil.

Corcept Therapeutics EBIT per Share Historical Data

The historical data trend for Corcept Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corcept Therapeutics EBIT per Share Chart

Corcept Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

0.91

1.03

0.99

0.97

0.96

Corcept Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															0.19	0.13	0.27	0.28	0.29

Corcept Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Corcept Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	107.282	/	111.742
=	0.96

Corcept Therapeutics's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	31.669	/	110.806
=	0.29

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.97

Corcept Therapeutics (NAS:CORT) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Corcept Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Corcept Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Corcept Therapeutics (Corcept Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corcept Therapeutics Inc (NAS:CORT) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

HTD:Germany

Address

149 Commonwealth Drive, Menlo Park, CA, USA, 94025

Website

https://www.corcept.com

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

Executives

Swisher Daniel N Jr	director	C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
William Guyer	officer: Chief Development Officer	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gary Charles Robb	officer: CHIEF FINANCIAL OFFICER	C/O 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph Douglas Lyon	officer: Chief Accounting Officer	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Sean Maduck	officer: See Remarks	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
David L Mahoney	director	SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
Hazel Hunt	officer: Chief Scientific Officer	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph K Belanoff	director, officer: CHIEF EXECUTIVE OFFICER	149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Baker G Leonard Jr	director, 10 percent owner	755 PAGE MILL ROAD, SUITE A-200, PALO ALTO CA 94304-1005
Joshua M. Murray	director	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Atabak Mokari	officer: Chief Financial Officer	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Gillian Cannon	director	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gregg H Alton	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Kimberly Park	director	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Andreas Grauer	officer: Chief Medical Officer	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025